OncoSec Medical Inc (NASDAQ:ONCS) shares are rising almost 8% ahead of the biotech firm’s immune data presentation tomorrow at the American Association for …
OncoSec Medical Inc (NASDAQ:ONCS) announced financial results for the fourth quarter and fiscal year ended July 31, 2016. “During the fourth quarter, we continued …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced Sharron Gargosky, PhD, has been appointed to Chief Clinical and Regulatory …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented preliminary findings from OMS-I130, a Phase II clinical trial of ImmunoPulse™ …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced at-the-market registered direct offering …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced key corporate objectives as well as financial results for the second …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the Company consolidated its three previous offices into one new …
Here’s what to watch for this week from GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Costco Wholesale Corporation (NASDAQ:COST), OncoSec Medical Inc (NASDAQ:ONCS), and AutoZone, Inc. (NYSE:AZO).
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company has closed its previously announced registered direct offering …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive agreements with institutional investors to …